Novartis allies with Voyager to develop gene therapies in $1.3bn deal
Novartis will pay Voyager $100m upfront and up to $1.2bn in milestone-based payments and royalties on net sales.
Novartis will pay Voyager $100m upfront and up to $1.2bn in milestone-based payments and royalties on net sales.
What's Your Reaction?
